Sarepta Therapeutics, Inc. $SRPT Shares Purchased by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS AM increased its stake in Sarepta Therapeutics by 54.8% in Q1, now owning approximately 0.47% of the company, valued at $29.57 million.
• Despite the positive adjustment in holdings, analysts have issued mixed ratings on the stock, with price targets being lowered by several firms, ranging from $14.00 to $24.00.
• Sarepta Therapeutics reported a significant 68.4% increase in revenue year-over-year for the last quarter, totaling $611.09 million, exceeding expectations.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 54.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 463,342 shares of the biotechnology company's stock after buying an additional 164,041 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.47% of Sarepta Therapeutics worth $29,570,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Sarepta Therapeutics by 4.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company's stock valued at $571,000 after acquiring an additional 218 shares during the period. UMB Bank n.a. grew its holdings in Sarepta Therapeutics by 53.0% in the first quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company's stock worth $51,000 after purchasing an additional 276 shares during the last quarter. State of Alaska Department of Revenue boosted its position in shares of Sarepta Therapeutics by 2.6% in the 1st quarter. State of Alaska Department of Revenue now owns 11,175 shares of the biotechnology company's stock worth $713,000 after purchasing an additional 285 shares in the last quarter. State of Michigan Retirement System raised its stake in Sarepta Therapeutics by 1.3% in the 1st quarter. State of Michigan Retirement System now owns 22,900 shares of the biotechnology company's stock worth $1,461,000 after acquiring an additional 300 shares during the last quarter. Finally, Louisiana State Employees Retirement System grew its position in Sarepta Therapeutics by 1.1% during the 1st quarter. Louisiana State Employees Retirement System now owns 26,800 shares of the biotechnology company's stock worth $1,710,000 after purchasing an additional 300 shares during the period. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Price Performance

SRPT traded down $1.09 during trading on Friday, reaching $17.43. 6,836,878 shares of the stock were exchanged, compared to its average volume of 7,114,391. The business's 50 day moving average price is $17.66 and its two-hundred day moving average price is $38.30. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -20.03 and a beta of 0.49. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $138.81. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $1.13. The firm had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.Sarepta Therapeutics's revenue was up 68.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.07 EPS. As a group, equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

SRPT has been the topic of several analyst reports. Guggenheim restated a "buy" rating and set a $22.00 price target on shares of Sarepta Therapeutics in a research report on Monday, September 15th. TD Cowen downgraded shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 price objective on the stock. in a report on Wednesday, June 18th. William Blair restated an "outperform" rating on shares of Sarepta Therapeutics in a report on Tuesday, July 29th. Citigroup assumed coverage on Sarepta Therapeutics in a research note on Tuesday, July 22nd. They issued a "sell" rating for the company. Finally, HC Wainwright reissued a "sell" rating on shares of Sarepta Therapeutics in a research note on Monday, August 25th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $39.32.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.